Clinical Trials Arena on MSN4d
Antag commences trial of GIPR antagonist for treating obesity
Antag Therapeutics has initiated a first-in-human, double-blind Phase Ia trial of the glucose-dependent insulinotropic ...
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...
American Association of Individual Investors7d
Why Structure Therapeutics Inc.’s (GPCR) Stock Is Down 12.27%
Structure Therapeutics Inc.’s GPCR share price has dipped by 12.27%, which has investors questioning if this is right time to buy.
Morningstar5d
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
The development of AT-7687 builds on the groundbreaking discovery of an endogenous GIPR antagonist by Professors Jens Holst, renowned for his discovery of GLP-1, and Mette Rosenkilde. In addition ...
Business Insider4d
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com. Contacts for Terns Investors Kaytee Bock [email protected] Media Jenna Urban ...
Yahoo Finance5d
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist. AT-7687 is designed to offer a new approach to obesity treatment by targeting the GIPR, a mechanism with ...